Bempedoic acid (Esperion Therapeutics) is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis. It is believed to work by inhibiting ATP citrate lyase (ACL) and by interacting with acyl-CoA synthase to increase the adenosine monophosphate (AMP)/ATP ratio to activate AMP-kinase. However, the precise mechanism of action is still unclear.
Esperion Therapeutics is also pursuing approval of a fixed-dose combination of bempedoic acid and generically available ezetimibe. Ezetimibe lowers cholesterol absorption in the small intestine by inhibiting Niemann-Pick C1-like 1 protein (NPC1L1).
LIST OF FIGURES
12 Figure 1: Datamonitor Healthcare’s drug assessment summary of bempedoic acid for dyslipidemia
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of bempedoic acid for dyslipidemia
16 Figure 3: Bempedoic acid +/- ezetimibe sales for dyslipidemia across the US, Japan, and five major EU markets, by country, 2018–27
LIST OF TABLES
6 Table 1: Recent high-impact events for bempedoic acid in dyslipidemia
7 Table 2: Bempedoic acid drug profile
8 Table 3: Bempedoic acid/ezetimibe FDC drug profile
9 Table 4: Bempedoic acid, change in LDL-C vs placebo
10 Table 5: Clinical trials for bempedoic acid and bempedoic acid/ezetimibe FDC in dyslipidemia
11 Table 6: Bempedoic acid for dyslipidemia – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.